Clinical Trial Update: A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Genentech is evaluating GDC-4198 alone and in combination with giredestrant versus abemaciclib plus giredestrant in locally advanced or metastatic estrogen rece…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• GDC-4198 (GDC-4198)
• Giredestrant (giredestrant)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING